These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 14707788)

  • 21. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
    Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
    BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects.
    Carosi ; Lazzarin ; Stellbrink ; Moyle ; Rugina ; Staszewski ; Givens ; Ross ; Granier ; Ait-Khaled ; Leather ; Nichols
    HIV Clin Trials; 2009; 10(6):356-67. PubMed ID: 20133266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland.
    Nadal D; Steiner F; Cheseaux JJ; Lazarevitch CA; Aebi C; Kind C; Rudin C
    Infection; 2000 Sep; 28(5):287-96. PubMed ID: 11073135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
    McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW
    Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.
    Paediatric European Network for Treatment of AIDS (PENTA)
    Lancet; 2002 Mar; 359(9308):733-40. PubMed ID: 11888583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
    Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P
    Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.
    Bryson YJ; Mirochnick M; Stek A; Mofenson LM; Connor J; Capparelli E; Watts DH; Huang S; Hughes MD; Kaiser K; Purdue L; Asfaw Y; Keller M; Smith E;
    HIV Clin Trials; 2008; 9(2):115-25. PubMed ID: 18474496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
    Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
    HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
    Haubrich R; Thompson M; Schooley R; Lang W; Stein A; Sereni D; van der Ende ME; Antunes F; Richman D; Pagano G; Kahl L; Fetter A; Brown DJ; Clumeck N
    AIDS; 1999 Dec; 13(17):2411-20. PubMed ID: 10597783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
    Kumar P; DeJesus E; Huhn G; Sloan L; Small CB; Edelstein H; Felizarta F; Hao R; Ross L; Stancil B; Pappa K; Ha B;
    BMC Infect Dis; 2013 Jun; 13():269. PubMed ID: 23741991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
    Eron J; Yeni P; Gathe J; Estrada V; DeJesus E; Staszewski S; Lackey P; Katlama C; Young B; Yau L; Sutherland-Phillips D; Wannamaker P; Vavro C; Patel L; Yeo J; Shaefer M;
    Lancet; 2006 Aug; 368(9534):476-82. PubMed ID: 16890834
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
    Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
    Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
    Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
    Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
    AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.